Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD.
暂无分享,去创建一个
Samin K. Sharma | M. Krucoff | G. Dangas | G. Weisz | D. Dudek | S. Mehta | R. Mehran | K. Huber | U. Baber | R. Kornowski | D. Cohen | C. Gibson | V. Kunadian | C. Briguori | D. Moliterno | S. Sartori | D. Cao | S. Pocock | D. Angiolillo | J. Escaned | R. Gil | U. Kaul | E. Ohman | K. Oldroyd | G. Sardella | R. Shlofmitz | B. Witzenbichler | T. Collier | G. Stefanini | Zhongjie Zhang | D. Cohen | D. Cohen | C. Gibson
[1] R. Mehran,et al. Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. , 2020, European heart journal.
[2] Y. Jang,et al. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. , 2020, JAMA.
[3] G. Condorelli,et al. Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis , 2020, The Lancet.
[4] Samin K. Sharma,et al. Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. , 2020, Journal of the American College of Cardiology.
[5] P. Serruys,et al. Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial , 2020, Clinical Research in Cardiology.
[6] Samin K. Sharma,et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. , 2019, The New England journal of medicine.
[7] Yong Hwan Park,et al. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. , 2019, JAMA.
[8] H. Okayama,et al. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. , 2019, JAMA.
[9] M. Price,et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk , 2019, European heart journal.
[10] D. Angiolillo,et al. P2Y12-ADP Receptor Blockade in Chronic Kidney Disease Patients With Acute Coronary Syndromes. , 2018, Circulation.
[11] A. Van Schepdael,et al. Oxidative stress in chronic kidney disease , 2018, Pediatric Nephrology.
[12] A. Algra,et al. Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a cohort study , 2018, Journal of thrombosis and haemostasis : JTH.
[13] Deepak L. Bhatt,et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials , 2017, The Lancet.
[14] Lorien S. Dalrymple,et al. Absolute Rates of Heart Failure, Coronary Heart Disease, and Stroke in Chronic Kidney Disease: An Analysis of 3 Community-Based Cohort Studies , 2016, JAMA cardiology.
[15] S. Pocock,et al. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. , 2016, American heart journal.
[16] C. Held,et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial , 2016, European heart journal.
[17] S. Pocock,et al. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. , 2016, Journal of the American College of Cardiology.
[18] A. Garg,et al. The Risk of Major Hemorrhage with CKD. , 2016, Journal of the American Society of Nephrology : JASN.
[19] S. Schulman,et al. Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.
[20] Peter L Duffy,et al. Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. , 2015, Journal of the American College of Cardiology.
[21] M. Woodward,et al. Kidney measures beyond traditional risk factors for cardiovascular prediction: A collaborative meta-analysis , 2015, The lancet. Diabetes & endocrinology.
[22] Peter L Duffy,et al. Prevalence and Impact of High Platelet Reactivity in Chronic Kidney Disease: Results From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Registry , 2015, Circulation. Cardiovascular interventions.
[23] P. Serruys,et al. The Impact of Renal Impairment on Long-Term Safety and Effectiveness of Drug-Eluting Stents , 2014, PloS one.
[24] Jeroen J. Bax,et al. Third universal definition of myocardial infarction. , 2012, Journal of the American College of Cardiology.
[25] D. Angiolillo,et al. Antithrombotic Therapy in Patients With Chronic Kidney Disease , 2012, Circulation.
[26] P. Serruys,et al. Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes. , 2012, JACC. Cardiovascular imaging.
[27] Marco Valgimigli,et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.
[28] J. Jakubowski,et al. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation , 2011, Journal of thrombosis and haemostasis : JTH.
[29] O. Morel,et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. , 2011, Journal of the American College of Cardiology.
[30] J. Ware,et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. , 2009, European heart journal.
[31] Deepak L. Bhatt,et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). , 2009, The American journal of cardiology.
[32] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[33] R. Califf,et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. , 2008, American heart journal.
[34] Deepak L. Bhatt. Intensifying platelet inhibition--navigating between Scylla and Charybdis. , 2007, The New England journal of medicine.
[35] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[36] S. Yusuf,et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel , 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[37] Charles E McCulloch,et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.
[38] K. Mann,et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. , 1991, Annals of internal medicine.
[39] J. Lutz,et al. Haemostasis in chronic kidney disease. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[40] M. Keltai,et al. Coronary Heart Disease Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial , 2010 .
[41] Kdoqi Disclaimer. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[42] Frans Van de Werf,et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.